SHARE
The UK will reach the threshold of herd immunity against Covid-19 on April 12, according to modelling by University College London, as vaccines “break the link” between cases and deaths.
Scientists said the proportion
of people who have protection against the virus – either through vaccines, natural immunity or through previous infection – will hit 73.4 per cent next Monday.
A separate study by Imperial College London found infections had fallen by about 60 per cent since February – but the data suggests the decline is levelling off.
While the decline in cases had stalled – possibly caused by
the reopening of schools and increased social mixing – deaths did not follow the same pattern.
Afgørende vaccine for Danmark kan have samme problem som AstraZenecas bt.dk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bt.dk Daily Mail and Mail on Sunday newspapers.
BBC News
Published
A Covid vaccine being manufactured in Scotland has reported a 90% immune response in early trials.
Biotech company Valneva tested its vaccine on 153 people and concluded it was safe and generally well tolerated.
The company will move to phase three by testing up to 5,000 people, some of whom will be recruited in Scotland.
UK Health Secretary Matt Hancock said if approved, the vaccine would play an important role in protecting communities.
Valneva, which manufactures its Covid vaccine at a plant in Livingston, said the results of their phase one/two study showed the vaccine was highly immunogenic with more than 90% of all study participants developing significant levels of antibodies to the Covid virus spike protein.
Oxford halts use of AstraZeneca vaccine in children s trial
Wednesday April 07 2021
A health worker holds a vial of the Oxford/AstraZeneca vaccine against Covid-19 amid the novel coronavirus pandemic, in Bogota on April 5, 2021. PHOTO | AFP
Summary
As several European countries suspend their rollout of the Oxford-AstraZeneca coronavirus vaccine, many African countries are continuing with it, as a principal jab.
Advertisement
The University of Oxford has halted administering doses of the Covid-19 vaccine it developed with AstraZeneca to children, pending further information about rare blood-clotting issues in adults who have received it.
The trial of the Oxford/AstraZeneca Covid-19 vaccine on children, aimed at assessing whether the jab produces a strong immune response in those aged between six and 17, started mid February.